Peripheral blood CD4+/CD8+ T cell ratio may have potential for predicting the treatment response of durvalumab plus tremelimumab therapy (STRIDE) for unresectable hepatocellular carcinoma: Preliminary report
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The CD4+/CD8+ T cell ratio in peripheral blood may predict treatment response to durvalumab plus tremelimumab (STRIDE) therapy in hepatocellular carcinoma (HCC) patients. A higher ratio showed a significantly greater objective response rate.
Area Of Science
- Immunology
- Oncology
- Biomarker Discovery
Background
- Hepatocellular carcinoma (HCC) remains a significant health challenge.
- Predicting response to immunotherapy is crucial for optimizing treatment strategies.
Purpose Of The Study
- To evaluate the clinical utility of peripheral blood T lymphocyte differentiation patterns.
- To determine if the CD4+/CD8+ T cell ratio can predict response to durvalumab plus tremelimumab (STRIDE) therapy in HCC patients.
Main Methods
- A cohort of 21 unresectable HCC patients treated with STRIDE was analyzed.
- Peripheral blood T lymphocyte differentiation patterns, specifically the CD4+/CD8+ T cell ratio, were assessed pretreatment.
- Treatment response was evaluated using modified RECIST criteria.
Main Results
- Five out of 21 patients (24%) achieved an objective response (OR).
- A pretreatment CD4+/CD8+ T cell ratio ≥2.5 was associated with a significantly higher OR rate (57%) compared to a ratio <2.5 (7%) (p=0.025).
- The optimal cutoff for predicting OR was determined to be 2.5.
Conclusions
- The peripheral blood CD4+/CD8+ T cell ratio shows potential as a predictive biomarker for STRIDE therapy response.
- This finding could aid in patient selection for immunotherapy in HCC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.